Histone deacetylase inhibition is cytotoxic to oligodendrocyte precursor cells in vitro and in vivo

International Journal of Developmental Neuroscience

Volumn 54, Issue , 2016, Pages 53-61

  Dincman, Toros A ^a   Beare, Jason E ^b   Ohri, Sujata Saraswat ^b   Gallo, Vittorio ^c   Hetman, Michal ^b   Whittemore, Scott R ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b University of Louisville School of Medicine   (United States)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

Chemotherapy induced cognitive impairment; Cytotoxicity; Histone deacetylase; Histone deacetylase inhibitor; Oligodendrocyte precursor cell; Suberoylanilide hydroxamic acid

Indexed keywords

CASPASE 3; CASPASE INHIBITOR; HISTONE DEACETYLASE; ISOENZYME; Q VD OPH; UNCLASSIFIED DRUG; VORINOSTAT; 2',3' CYCLIC NUCLEOTIDE 3' PHOSPHODIESTERASE; CASPASE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASTROCYTE; BRAIN DEVELOPMENT; CELL SURVIVAL; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; EFFECTIVE DOSE (PHARMACOLOGY); ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME LOCALIZATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MYELINATION; NERVE CELL DIFFERENTIATION; NERVE CELL NECROSIS; NONHUMAN; OLIGODENDROCYTE PROGENITOR; OLIGODENDROGLIA; POSTNATAL DEVELOPMENT; PRIMARY CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSFORMED CELL LINE; ANIMAL; BRAIN CORTEX; C57BL MOUSE; CELL CULTURE; CELL PROLIFERATION; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; MAMMALIAN EMBRYO; METABOLISM; NEWBORN; PHYSIOLOGY; STEM CELL; TIME FACTOR; TRANSGENIC MOUSE;

2',3'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; ANIMALS; ANIMALS, NEWBORN; CASPASES; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CEREBRAL CORTEX; DOSE-RESPONSE RELATIONSHIP, DRUG; EMBRYO, MAMMALIAN; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HYDROXAMIC ACIDS; IN VITRO TECHNIQUES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OLIGODENDROGLIA; STEM CELLS; TIME FACTORS;

EID: 84987648081     PISSN: 07365748     EISSN: 1873474X     Source Type: Journal    
DOI: 10.1016/j.ijdevneu.2016.08.006     Document Type: Article

References (74)

1. Abel, T., Zukin, R.S., Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. Curr. Opin. Pharmacol. 8 (2008), 57–64.
2. Ahles, T.A., Saykin, A.J., Candidate mechanisms for chemotherapy-induced cognitive changes. Nat. Rev. Cancer 7 (2007), 192–201.
3. Argyriou, A.A., Assimakopoulos, K., Iconomou, G., Giannakopoulou, F., Kalofonos, H.P., Either called chemobrain or chemofog, the long-term chemotherapy-induced cognitive decline in cancer survivors is real. J. Pain Symptom Manage., 2010.
4. Baltan, S., Murphy, S.P., Danilov, C.A., Bachleda, A., Morrison, R.S., Histone deacetylase inhibitors preserve white matter structure and function during ischemia by conserving ATP and reducing excitotoxicity. J. Neurosci. 31 (2011), 3990–3999.
5. Baltan, S., Morrison, R.S., Murphy, S.P., Novel protective effects of histone deacetylase inhibition on stroke and white matter ischemic injury. Neurother.: J. Am. Soc. Exp. Neurother. 10 (2013), 798–807.
6. Baltan, S., Histone deacetylase inhibitors preserve function in aging axons. J. Neurochem. 123:Suppl. 2 (2012), 108–115.
7. Bardai, F.H., D'Mello, S.R., Selective toxicity by HDAC3 in neurons: regulation by Akt and GSK3beta. J. Neurosci. 31 (2011), 1746–1751.
8. Bardai, F.H., Price, V., Zaayman, M., Wang, L., D'Mello, S.R., Histone deacetylase-1 (HDAC1) is a molecular switch between neuronal survival and death. J. Biol. Chem. 287 (2012), 35444–35453.
9. Bertrand, P., Inside HDAC with HDAC inhibitors. Eur. J. Med. Chem. 45 (2010), 2095–2116.
10. Bolden, J.E., Peart, M.J., Johnstone, R.W., Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5 (2006), 769–784.
11. Briones, T.L., Woods, J., Chemotherapy-induced cognitive impairment is associated with decreases in cell proliferation and histone modifications. BMC Neurosci., 12, 2011, 124.
12. Butler, L.M., Agus, D.B., Scher, H.I., Higgins, B., Rose, A., Cordon-Cardo, C., Thaler, H.T., Rifkind, R.A., Marks, P.A., Richon, V.M., Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 60 (2000), 5165–5170.
13. Chen, S., Wu, H., Ossola, B., Schendzielorz, N., Wilson, B., Chu, C., Wang, Q., Zhang, D., Qian, L., Li, X., Hong, J., Lu, R., Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, protects dopaminergic neurons from neurotoxin-induced damage. Br. J. Pharmacol., 2011.
14. Chen, H.Y., Yang, Y.M., Han, R., Noble, M., MEK1/2 inhibition suppresses tamoxifen toxicity on CNS glial progenitor cells. J. Neurosci. 33 (2013), 15069–15074.
15. Chen, S., Zhao, Y., Gou, W.F., Zhao, S., Takano, Y., Zheng, H.C., The anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) on the aggressive phenotypes of ovarian carcinoma cells. PLoS One, 8, 2013, e79781.
16. Cheriyath, V., Kuhns, M.A., Kalaycio, M.E., Borden, E.C., Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma. Br. J. Cancer 104 (2011), 957–967.
17. Christie, L.A., Acharya, M.M., Parihar, V.K., Nguyen, A., Martirosian, V., Limoli, C.L., Impaired cognitive function and hippocampal neurogenesis following cancer chemotherapy. Clin. Cancer Res. 18 (2012), 1954–1965.
18. Colussi, C., Illi, B., Rosati, J., Spallotta, F., Farsetti, A., Grasselli, A., Mai, A., Capogrossi, M.C., Gaetano, C., Histone deacetylase inhibitors: keeping momentum for neuromuscular and cardiovascular diseases treatment. Pharmacol. Res.: Off. J. Ital. Pharmacol. Soc. 62 (2010), 3–10.
19. Conway, G.D., O'Bara, M.A., Vedia, B.H., Pol, S.U., Sim, F.J., Histone deacetylase activity is required for human oligodendrocyte progenitor differentiation. Glia 60 (2012), 1944–1953.
20. Deutsch, S.I., Rosse, R.B., Mastropaolo, J., Long, K.D., Gaskins, B.L., Epigenetic therapeutic strategies for the treatment of neuropsychiatric disorders: ready for prime time?. Clin. Neuropharmacol. 31 (2008), 104–119.
21. Di Bernardo, G., Squillaro, T., Dell'Aversana, C., Miceli, M., Cipollaro, M., Cascino, A., Altucci, L., Galderisi, U., Histone deacetylase inhibitors promote apoptosis and senescence in human mesenchymal stem cells. Stem Cells Dev. 18 (2009), 573–581.
22. Dietrich, J., Han, R., Yang, Y., Mayer-Proschel, M., Noble, M., CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J. Biol., 5, 2006, 22.
23. Dietz, K.C., Casaccia, P., HDAC inhibitors and neurodegeneration: at the edge between protection and damage. Pharmacol. Res.: Off. J. Ital. Pharmacol. Soc. 62 (2010), 11–17.
24. Dincman, T.A., Beare, J.E., Ohri, S.S., Whittemore, S.R., Isolation of cortical mouse oligodendrocyte precursor cells. J. Neurosci. Methods 209 (2012), 219–226.
25. Dong, G., Wang, L., Wang, C.Y., Yang, T., Kumar, M.V., Dong, Z., Induction of apoptosis in renal tubular cells by histone deacetylase inhibitors, a family of anticancer agents. J. Pharmacol. Exp. Ther. 325 (2008), 978–984.
26. Forgione, N., Tropepe, V., Histone deacetylase inhibition promotes caspase-independent cell death of ventral midbrain neurons. Mol. Cell. Neurosci., 2011.
27. Ge, Z., Da, Y., Xue, Z., Zhang, K., Zhuang, H., Peng, M., Li, Y., Li, W., Simard, A., Hao, J., Yao, Z., Zhang, R., Vorinostat, a histone deacetylase inhibitor, suppresses dendritic cell function and ameliorates experimental autoimmune encephalomyelitis. Exp. Neurol. 241 (2013), 56–66.
28. Grayson, D.R., Kundakovic, M., Sharma, R.P., Is there a future for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders?. Mol. Pharmacol. 77 (2010), 126–135.
29. Han, R., Yang, Y.M., Dietrich, J., Luebke, A., Mayer-Proschel, M., Noble, M., Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. J. Biol., 7, 2008, 12.
30. Hanson, J.E., La, H., Plise, E., Chen, Y.H., Ding, X., Hanania, T., Sabath, E.V., Alexandrov, V., Brunner, D., Leahy, E., Steiner, P., Liu, L., Scearce-Levie, K., Zhou, Q., SAHA enhances synaptic function and plasticity in vitro but has limited brain availability in vivo and does not impact cognition. PLoS One, 8, 2013, e69964.
31. Hockly, E., Richon, V.M., Woodman, B., Smith, D.L., Zhou, X., Rosa, E., Sathasivam, K., Ghazi-Noori, S., Mahal, A., Lowden, P.A., Steffan, J.S., Marsh, J.L., Thompson, L.M., Lewis, C.M., Marks, P.A., Bates, G.P., Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 2041–2046.
32. Institute of Laboratory Animal Resources Commission on Life Sciences National Research Council, Guide for the Care and Use of Laboratory Animals. 1996, Washington, DC, National Academy Press.
33. Kazantsev, A.G., Thompson, L.M., Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat. Rev. Drug Discov. 7 (2008), 854–868.
34. Kidd, S.K., Schneider, J.S., Protection of dopaminergic cells from MPP+-mediated toxicity by histone deacetylase inhibition. Brain Res. 1354 (2010), 172–178.
35. Kim, H.J., Chuang, D.M., HDAC inhibitors mitigate ischemia-induced oligodendrocyte damage: potential roles of oligodendrogenesis, VEGF, and anti-inflammation. Am. J. Trans. Res. 6 (2014), 206–223.
36. Kim, D., Frank, C.L., Dobbin, M.M., Tsunemoto, R.K., Tu, W., Peng, P.L., Guan, J.S., Lee, B.H., Moy, L.Y., Giusti, P., Broodie, N., Mazitschek, R., Delalle, I., Haggarty, S.J., Neve, R.L., Lu, Y., Tsai, L.H., Deregulation of HDAC1 by p25/Cdk5 in neurotoxicity. Neuron 60 (2008), 803–817.
37. Komatsu, N., Kawamata, N., Takeuchi, S., Yin, D., Chien, W., Miller, C.W., Koeffler, H.P., SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells. Oncol. Rep. 15 (2006), 187–191.
38. Lange, M., Rigal, O., Clarisse, B., Giffard, B., Sevin, E., Barillet, M., Eustache, F., Joly, F., Cognitive dysfunctions in elderly cancer patients: a new challenge for oncologists. Cancer Treatment Rev. 40 (2014), 810–817.
39. Lee, J.H., Choy, M.L., Ngo, L., Foster, S.S., Marks, P.A., Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 14639–14644.
40. Li, H., Richardson, W.D., Genetics meets epigenetics: HDACs and Wnt signaling in myelin development and regeneration. Nat. Neurosci. 12 (2009), 815–817.
41. Liu, D.X., Nath, N., Chellappan, S.P., Greene, L.A., Regulation of neuron survival and death by p130 and associated chromatin modifiers. Genes Develop. 19 (2005), 719–732.
42. Liu, X.S., Chopp, M., Kassis, H., Jia, L.F., Hozeska-Solgot, A., Zhang, R.L., Chen, C., Cui, Y.S., Zhang, Z.G., Valproic acid increases white matter repair and neurogenesis after stroke. Neuroscience 220 (2012), 313–321.
43. Lv, L., Sun, Y., Han, X., Xu, C.C., Tang, Y.P., Dong, Q., Valproic acid improves outcome after rodent spinal cord injury: potential roles of histone deacetylase inhibition. Brain Res. 1396 (2011), 60–68.
44. Lv, L., Han, X., Sun, Y., Wang, X., Dong, Q., Valproic acid improves locomotion in vivo after SCI and axonal growth of neurons in vitro. Exp. Neurol. 233 (2012), 783–790.
45. Lytle, J.M., Chittajallu, R., Wrathall, J.R., Gallo, V., NG2 cell response in the CNP-EGFP mouse after contusive spinal cord injury. Glia 57 (2009), 270–285.
46. Machado-Vieira, R., Ibrahim, L., Zarate, C.A. Jr., Histone deacetylases and mood disorders: epigenetic programming in gene-environment interactions. CNS Neurosci. Ther. 17 (2011), 699–704.
47. Marin-Husstege, M., Muggironi, M., Liu, A., Casaccia-Bonnefil, P., Histone deacetylase activity is necessary for oligodendrocyte lineage progression. J. Neurosci. 22 (2002), 10333–10345.
48. Marks, P.A., Discovery and development of SAHA as an anticancer agent. Oncogene 26 (2007), 1351–1356.
49. Marks, P.A., The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin. Investig. Drugs 19 (2010), 1049–1066.
50. McGee-Lawrence, M.E., McCleary-Wheeler, A.L., Secreto, F.J., Razidlo, D.F., Zhang, M., Stensgard, B.A., Li, X., Stein, G.S., Lian, J.B., Westendorf, J.J., Suberoylanilide hydroxamic acid (SAHA; vorinostat) causes bone loss by inhibiting immature osteoblasts. Bone 48 (2011), 1117–1126.
51. Miller, R.H., Mi, S., Dissecting demyelination. Nat. Neurosci. 10 (2007), 1351–1354.
52. Monje, M., Cranial radiation therapy and damage to hippocampal neurogenesis. Dev. Disabil. Res. Rev. 14 (2008), 238–242.
53. Mosmann, T., Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65 (1983), 55–63.
54. Nishiyama, A., Komitova, M., Suzuki, R., Zhu, X., Polydendrocytes (NG2 cells): multifunctional cells with lineage plasticity. Nat. Rev. Neurosci. 10 (2009), 9–22.
55. Noble, M., Wren, D., Wolswijk, G., The O-2A(adult) progenitor cell: a glial stem cell of the adult central nervous system. Semin. Cell Biol. 3 (1992), 413–422.
56. Pedre, X., Mastronardi, F., Bruck, W., Lopez-Rodas, G., Kuhlmann, T., Casaccia, P., Changed histone acetylation patterns in normal-appearing white matter and early multiple sclerosis lesions. J. Neurosci. 31 (2011), 3435–3445.
57. Petruccelli, L.A., Dupere-Richer, D., Pettersson, F., Retrouvey, H., Skoulikas, S., Miller, W.H. Jr., Vorinostat induces reactive oxygen species and DNA damage in acute myeloid leukemia cells. PLoS One, 6, 2011, e20987.
58. Salminen, A., Tapiola, T., Korhonen, P., Suuronen, T., Neuronal apoptosis induced by histone deacetylase inhibitors. Brain Res. Mol. Brain Res. 61 (1998), 203–206.
59. Shen, S., Casaccia-Bonnefil, P., Post-translational modifications of nucleosomal histones in oligodendrocyte lineage cells in development and disease. J. Mol. Neurosci. 35 (2008), 13–22.
60. Shen, S., Sandoval, J., Swiss, V.A., Li, J., Dupree, J., Franklin, R.J., Casaccia-Bonnefil, P., Age-dependent epigenetic control of differentiation inhibitors is critical for remyelination efficiency. Nat. Neurosci. 11 (2008), 1024–1034.
61. Sidman, R.L., Kosaras, B., Misra, B., Senft, S. High resolution mouse brain atlas, available from www.hms.harvard.edu/research/brain/atlas.html, (last accessed 2016).
62. Swiss, V.A., Nguyen, T., Dugas, J., Ibrahim, A., Barres, B., Androulakis, I.P., Casaccia, P., Identification of a gene regulatory network necessary for the initiation of oligodendrocyte differentiation. PLoS One, 6, 2011, e18088.
63. Tager, F.A., McKinley, P.S., Schnabel, F.R., El-Tamer, M., Cheung, Y.K., Fang, Y., Golden, C.R., Frosch, M.E., Habif, U., Mulligan, M.M., Chen, I.S., Hershman, D.L., The cognitive effects of chemotherapy in post-menopausal breast cancer patients: a controlled longitudinal study. Breast Cancer Res. Treat. 123 (2010), 25–34.
64. Thomas, E.A., Focal nature of neurological disorders necessitates isotype-selective histone deacetylase (HDAC) inhibitors. Mol. Neurobiol. 40 (2009), 33–45.
65. Tsankova, N., Renthal, W., Kumar, A., Nestler, E.J., Epigenetic regulation in psychiatric disorders. Nat. Rev. Neurosci. 8 (2007), 355–367.
66. Vardy, J., Dhillon, H., The fog hasn't lifted on “chemobrain” yet: ongoing uncertainty regarding the effects of chemotherapy and breast cancer on cognition. Breast Cancer Res. Treat. 123 (2010), 35–37.
67. Vashishta, A., Hetman, M., Inhibitors of histone deacetylases enhance neurotoxicity of DNA damage. Neuromolecular Med., 2014.
68. Wang, Y., Wang, X., Liu, L., HDAC inhibitor trichostatin A-inhibited survival of dopaminergic neuronal cells. Neurosci. Lett. 467 (2009), 212–216.
69. Wolswijk, G., Noble, M., Identification of an adult-specific glial progenitor cell. Development 105 (1989), 387–400.
70. Ye, F., Chen, Y., Hoang, T., Montgomery, R.L., Zhao, X.H., Bu, H., Hu, T., Taketo, M.M., van Es, J.H., Clevers, H., Hsieh, J., Bassel-Duby, R., Olson, E.N., Lu, Q.R., HDAC1 and HDAC2 regulate oligodendrocyte differentiation by disrupting the beta-catenin-TCF interaction. Nat. Neurosci. 12 (2009), 829–838.
71. Yin, D., Ong, J.M., Hu, J., Desmond, J.C., Kawamata, N., Konda, B.M., Black, K.L., Koeffler, H.P., Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo. Clin. Cancer Res. 13 (2007), 1045–1052.
72. Yu, Y., Casaccia, P., Lu, Q.R., Shaping the oligodendrocyte identity by epigenetic control. Epigenetics 5 (2010), 124–128.
73. Yuan, X., Chittajallu, R., Belachew, S., Anderson, S., McBain, C.J., Gallo, V., Expression of the green fluorescent protein in the oligodendrocyte lineage: a transgenic mouse for developmental and physiological studies. J. Neurosci. Res. 70 (2002), 529–545.
74. Zachariae, R., Mehlsen, M.Y., Is chemotherapy associated with cognitive impairment?. Nat. Rev. Urol. 8 (2011), 2–183.